Pro Dex Inc. PDEX
Medical/Dental Instruments · data as of November 13, 2026
Pro Dex Inc. (PDEX) is a healthcare company listed in the US with a market value of about $210M. In the twelve months to September 30, 2026 it had revenue of $80M and net income of $12M, a net margin of 15.1%.
Its overall Stock Analiz score is 4.0 out of 5 (excellent). The strongest part is track record (5/5); the weakest is future growth (3/5).
Key numbers: a P/E of 18.1, a price to free cash flow of 19.7, 5-year revenue growth of 15% a year, a 5-year average ROIC of 13%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 26% below the current price.
About Pro Dex
Pro Dex is listed in the US and classified in medical/dental instruments. Revenue went from $38M in 2021 to $78M in 2026, growth of about 15.3% a year. It was profitable in 6 of the last 6 years in our data. Its share count fell by 9% over three years (buybacks). It spends 4% of revenue on research and development.
Score: 4.0 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 5-year EPS growth above 10% a year
Checks not passed
- Price below intrinsic value (DCF, moderate assumptions)
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
- Pays a dividend
- Dividend 3 years in a row
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|---|
| Revenue | $80M | $78M | $67M | $54M | $46M | $42M | $38M |
| Net income | $12M | $14M | $9M | $2M | $7M | $5M | $6M |
| Free cash flow | $11M | $7M | -$3M | — | — | -$2M | -$4M |
| EPS (diluted) | $3.63 | $4.12 | $2.67 | $0.60 | $1.95 | $1.21 | $1.57 |
| Net margin | 15.1% | 17.6% | 13.5% | 4.0% | 15.3% | 10.9% | 16.2% |
| ROIC | — | 15.0% | 15.1% | 13.2% | 9.4% | 9.9% | 10.0% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 1 analysts is $74.00, 13% above the current price; targets range from $74.00 to $74.00; the consensus rating is “none”; expected EPS is $3.09 for the fiscal year ending June 30, 2027.
Frequently asked questions
What is Pro Dex’s P/E ratio?
About 18.1, based on the last twelve months of diluted earnings per share (forward P/E about 20.4).
Is Pro Dex stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 26% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Pro Dex pay a dividend?
Not currently.
Is Pro Dex a good stock to buy?
We do not give buy or sell advice. Pro Dex scores 4.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.